{
  "TP53": {
    "c.524G>A": {
      "protein": "p.R175H",
      "pathogenicity_score": 0.99,
      "cancer_types": [
        "breast",
        "lung",
        "colorectal",
        "ovarian",
        "sarcoma"
      ],
      "mechanism": "DNA binding domain hotspot - complete loss of transcriptional activity",
      "functional_impact": "Dominant negative effect on wild-type p53",
      "prognosis": "poor",
      "targeted_therapies": [
        "APR-246 (eprenetapopt)",
        "PRIMA-1MET"
      ],
      "response_rate": "Variable",
      "cosmic_id": "COSM10663",
      "cosmic_verified": true,
      "evidence_level": "Strong",
      "biomarker_status": "Established",
      "frequency_data": {
        "all_cancers": "5.4%",
        "breast": "1.2%",
        "lung": "2.1%",
        "colorectal": "3.8%"
      },
      "structural_consequence": "Disrupts DNA binding loop L2",
      "resistance_mechanisms": [],
      "clinical_trials": [
        "NCT03268382",
        "NCT03072043"
      ],
      "literature_pmids": [
        "25079317",
        "23636126",
        "22158963"
      ]
    },
    "c.818G>A": {
      "protein": "p.R273H",
      "pathogenicity_score": 0.98,
      "cancer_types": [
        "breast",
        "colorectal",
        "lung",
        "ovarian"
      ],
      "mechanism": "DNA binding domain mutation with gain-of-function properties",
      "functional_impact": "Dominant negative + oncomorphic functions",
      "prognosis": "poor",
      "targeted_therapies": [
        "APR-246",
        "Statins (GOF inhibition)"
      ],
      "response_rate": "Variable",
      "cosmic_id": "COSM10679",
      "cosmic_verified": true,
      "evidence_level": "Strong",
      "biomarker_status": "Established",
      "frequency_data": {
        "all_cancers": "3.2%",
        "breast": "0.8%",
        "colorectal": "2.1%",
        "lung": "1.4%"
      },
      "structural_consequence": "Alters major groove DNA contacts",
      "resistance_mechanisms": [
        "Enhanced metastasis",
        "Chemoresistance"
      ],
      "clinical_trials": [
        "NCT03268382"
      ],
      "literature_pmids": [
        "23636126",
        "25079317"
      ]
    },
    "c.733G>A": {
      "protein": "p.G245S",
      "pathogenicity_score": 0.96,
      "cancer_types": [
        "lung",
        "colorectal",
        "breast"
      ],
      "mechanism": "DNA binding domain structural disruption",
      "functional_impact": "Loss of DNA binding specificity",
      "prognosis": "poor",
      "targeted_therapies": [],
      "response_rate": "Variable",
      "cosmic_id": "COSM10676",
      "cosmic_verified": true,
      "evidence_level": "Strong",
      "biomarker_status": "Established",
      "frequency_data": {
        "all_cancers": "1.8%",
        "lung": "1.2%",
        "colorectal": "0.9%"
      },
      "structural_consequence": "",
      "resistance_mechanisms": [],
      "clinical_trials": [],
      "literature_pmids": []
    }
  },
  "KRAS": {
    "c.35G>A": {
      "protein": "p.G12D",
      "pathogenicity_score": 0.95,
      "cancer_types": [
        "pancreatic",
        "colorectal",
        "lung"
      ],
      "mechanism": "Impaired GTPase activity, constitutive activation",
      "functional_impact": "Oncogenic activation of RAS pathway",
      "prognosis": "poor_without_targeted_therapy",
      "targeted_therapies": [
        "MRTX1133 (investigational)"
      ],
      "response_rate": "Variable",
      "cosmic_id": "COSM521",
      "cosmic_verified": true,
      "evidence_level": "Strong",
      "biomarker_status": "Established",
      "frequency_data": {
        "pancreatic": "47%",
        "colorectal": "13%",
        "lung": "4%"
      },
      "structural_consequence": "Disrupts GAP-mediated GTP hydrolysis",
      "resistance_mechanisms": [
        "PI3K activation",
        "RTK feedback"
      ],
      "clinical_trials": [
        "NCT05737706"
      ],
      "literature_pmids": [
        "22589270",
        "23455880"
      ]
    },
    "c.34G>T": {
      "protein": "p.G12C",
      "pathogenicity_score": 0.94,
      "cancer_types": [
        "lung",
        "colorectal",
        "pancreatic"
      ],
      "mechanism": "Impaired GTPase activity, covalently targetable",
      "functional_impact": "Oncogenic RAS signaling",
      "prognosis": "moderate_with_therapy",
      "targeted_therapies": [
        "Sotorasib (FDA approved)",
        "Adagrasib (FDA approved)"
      ],
      "response_rate": "Variable",
      "cosmic_id": "COSM516",
      "cosmic_verified": true,
      "evidence_level": "Strong",
      "biomarker_status": "FDA_approved_target",
      "frequency_data": {
        "lung_adenocarcinoma": "13%",
        "colorectal": "3%",
        "pancreatic": "2%"
      },
      "structural_consequence": "Creates druggable cysteine pocket",
      "resistance_mechanisms": [
        "G12C reversion",
        "RTK amplification",
        "SHP2 mutations"
      ],
      "clinical_trials": [
        "NCT03600883",
        "NCT04330664"
      ],
      "literature_pmids": [
        "33883589",
        "34161619"
      ],
      "fda_approved_drugs": [
        "sotorasib",
        "adagrasib"
      ]
    },
    "c.35G>T": {
      "protein": "p.G12V",
      "pathogenicity_score": 0.93,
      "cancer_types": [
        "colorectal",
        "lung",
        "pancreatic"
      ],
      "mechanism": "Constitutive GTP binding, impaired GTPase",
      "functional_impact": "Strong oncogenic activation",
      "prognosis": "poor",
      "targeted_therapies": [
        "Investigational G12V inhibitors"
      ],
      "response_rate": "Variable",
      "cosmic_id": "COSM532",
      "cosmic_verified": true,
      "evidence_level": "Strong",
      "biomarker_status": "Established",
      "frequency_data": {
        "colorectal": "8%",
        "lung": "3%",
        "pancreatic": "21%"
      },
      "structural_consequence": "",
      "resistance_mechanisms": [],
      "clinical_trials": [],
      "literature_pmids": []
    }
  },
  "EGFR": {
    "c.2573T>G": {
      "protein": "p.L858R",
      "pathogenicity_score": 0.96,
      "cancer_types": [
        "lung_adenocarcinoma"
      ],
      "mechanism": "Constitutive tyrosine kinase activation",
      "functional_impact": "Oncogenic EGFR signaling",
      "prognosis": "excellent_with_targeted_therapy",
      "targeted_therapies": [
        "Erlotinib",
        "Gefitinib",
        "Osimertinib",
        "Afatinib"
      ],
      "response_rate": "70-80%",
      "cosmic_id": "COSM6224",
      "cosmic_verified": true,
      "evidence_level": "Strong",
      "biomarker_status": "FDA_approved_target",
      "frequency_data": {
        "lung_adenocarcinoma": "8%",
        "nsclc_overall": "12%"
      },
      "structural_consequence": "Activates kinase domain",
      "resistance_mechanisms": [
        "T790M (50%)",
        "MET amplification (15%)",
        "PIK3CA mutations"
      ],
      "clinical_trials": [],
      "literature_pmids": [
        "15118073",
        "21531810"
      ],
      "fda_approved_drugs": [
        "erlotinib",
        "gefitinib",
        "osimertinib",
        "afatinib"
      ]
    },
    "c.2369C>T": {
      "protein": "p.T790M",
      "pathogenicity_score": 0.94,
      "cancer_types": [
        "lung_adenocarcinoma"
      ],
      "mechanism": "Gatekeeper mutation, increased ATP affinity",
      "functional_impact": "Resistance to 1st/2nd generation TKIs",
      "prognosis": "moderate_with_3rd_gen_TKI",
      "targeted_therapies": [
        "Osimertinib (FDA approved)"
      ],
      "response_rate": "71%",
      "cosmic_id": "COSM6240",
      "cosmic_verified": true,
      "evidence_level": "Strong",
      "biomarker_status": "FDA_approved_target",
      "frequency_data": {
        "acquired_resistance": "50%",
        "de_novo": "2%"
      },
      "structural_consequence": "Steric hindrance to TKI binding",
      "resistance_mechanisms": [
        "C797S",
        "MET amplification",
        "EGFR amplification"
      ],
      "clinical_trials": [],
      "literature_pmids": [
        "16849602",
        "30531947"
      ],
      "fda_approved_drugs": [
        "osimertinib"
      ]
    }
  },
  "BRAF": {
    "c.1799T>A": {
      "protein": "p.V600E",
      "pathogenicity_score": 0.97,
      "cancer_types": [
        "melanoma",
        "colorectal",
        "thyroid",
        "lung"
      ],
      "mechanism": "Constitutive kinase activation, mimics phosphorylation",
      "functional_impact": "Oncogenic MAPK pathway activation",
      "prognosis": "moderate_with_targeted_therapy",
      "targeted_therapies": [
        "Vemurafenib",
        "Dabrafenib",
        "Encorafenib"
      ],
      "response_rate": "50-60%",
      "cosmic_id": "COSM476",
      "cosmic_verified": true,
      "evidence_level": "Strong",
      "biomarker_status": "FDA_approved_target",
      "frequency_data": {
        "melanoma": "40%",
        "thyroid_papillary": "45%",
        "colorectal": "8%",
        "lung": "2%"
      },
      "structural_consequence": "Disrupts auto-inhibitory interactions",
      "resistance_mechanisms": [
        "NRAS mutations",
        "MEK1 mutations",
        "RTK upregulation"
      ],
      "clinical_trials": [],
      "literature_pmids": [
        "15035987",
        "20179705"
      ],
      "fda_approved_drugs": [
        "vemurafenib",
        "dabrafenib",
        "encorafenib"
      ],
      "combination_therapy": "BRAF + MEK inhibitors"
    }
  },
  "PIK3CA": {
    "c.3140A>G": {
      "protein": "p.H1047R",
      "pathogenicity_score": 0.92,
      "cancer_types": [
        "breast",
        "colorectal",
        "endometrial"
      ],
      "mechanism": "Kinase domain activation, enhanced lipid kinase activity",
      "functional_impact": "Oncogenic PI3K/AKT pathway activation",
      "prognosis": "moderate_with_targeted_therapy",
      "targeted_therapies": [
        "Alpelisib (FDA approved)"
      ],
      "response_rate": "26%",
      "cosmic_id": "COSM775",
      "cosmic_verified": true,
      "evidence_level": "Strong",
      "biomarker_status": "FDA_approved_target",
      "frequency_data": {
        "breast": "18%",
        "colorectal": "7%",
        "endometrial": "24%"
      },
      "structural_consequence": "Disrupts auto-inhibitory contacts",
      "resistance_mechanisms": [],
      "clinical_trials": [],
      "literature_pmids": [
        "15016963",
        "31091374"
      ],
      "fda_approved_drugs": [
        "alpelisib"
      ],
      "combination_therapy": "PI3K inhibitor + fulvestrant"
    },
    "c.1624G>A": {
      "protein": "p.E542K",
      "pathogenicity_score": 0.89,
      "cancer_types": [
        "breast",
        "colorectal",
        "lung"
      ],
      "mechanism": "Helical domain mutation, enhanced membrane binding",
      "functional_impact": "Oncogenic PI3K activation",
      "prognosis": "moderate",
      "targeted_therapies": [
        "Alpelisib"
      ],
      "response_rate": "Variable",
      "cosmic_id": "COSM763",
      "cosmic_verified": true,
      "evidence_level": "Strong",
      "biomarker_status": "Targetable",
      "frequency_data": {
        "breast": "8%",
        "colorectal": "4%"
      },
      "structural_consequence": "",
      "resistance_mechanisms": [],
      "clinical_trials": [],
      "literature_pmids": []
    }
  }
}